| Patents for A61K 49 - Preparations for testing in vivo (35,376) |
|---|
| 01/05/2006 | DE102004062258B3 New hydroxypyrimidone, hydroxypyridinone or dihydroxybenzene derivatives useful for preparing conjugates of biomolecules useful as magnetic resonance contrast agents |
| 01/05/2006 | CA2571346A1 Imaging infection with compounds that bind to thymidine kinase |
| 01/05/2006 | CA2570687A1 Diagnostic agents for positron emission imaging using radiolabeled halogenated xanthenes and methods for positron emission imaging with radiolabeled halogenated xanthene diagnostic agents |
| 01/04/2006 | EP1611903A1 Agent for detecting sentinel lymph node and detection method |
| 01/04/2006 | EP1610805A2 Thiol-mediated drug attachment to targeting peptides |
| 01/04/2006 | EP1610752A2 Localized drug delivery using drug-loaded nanocapsules and implantable device coated with the same |
| 01/04/2006 | EP1610671A2 Polarized light devices and methods |
| 01/04/2006 | CN1717201A Ultrasound triggering method |
| 01/04/2006 | CN1714783A Implantable particles for tissue bulking and the treatment |
| 01/04/2006 | CN1234680C Image forming agent, its precursor and preparing process thereof |
| 01/04/2006 | CN1234415C Medical powder |
| 01/03/2006 | CA2191768C A diagnostic method for establishing food intolerance/allergy, and an instrument for use when carrying out the method |
| 01/03/2006 | CA2185350C Acridone-derived bisintercalators as chemotherapeutic agents |
| 12/29/2005 | WO2005123907A2 Ex-vivo application of solid microparticulate therapeutic agents |
| 12/29/2005 | WO2005123143A1 Method of predicting human drug-drug interactions using a non-human mammalian model |
| 12/29/2005 | WO2005123039A1 Abuse-deterrent drug formulations |
| 12/29/2005 | WO2005123023A1 Plural activating optical change toothpastes, stimuli and elements |
| 12/29/2005 | WO2005122891A1 Lipophilic derivatives of chelate monoamides |
| 12/29/2005 | WO2005106476A3 Method for diagnosing infectious diseases |
| 12/29/2005 | WO2005094364A3 Iga antibody protein as a cytotoxic drug |
| 12/29/2005 | WO2005091704A3 Magnetic nanoparticles of noble metals |
| 12/29/2005 | WO2005058373A3 Methods, program products, and systems for single and multi-agent dosing |
| 12/29/2005 | WO2005049096A3 Protein and polymer conjugates as chelants with enhanced blood retention |
| 12/29/2005 | WO2005016259A3 Polymersomes incorporating highly emissive probes |
| 12/29/2005 | WO2004103269A3 Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of the genus borrelia |
| 12/29/2005 | WO2004005320A3 ErbB-2 RECEPTOR TARGETING PEPTIDE |
| 12/29/2005 | US20050288323 Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine |
| 12/29/2005 | US20050287563 Nucleic acid labeling compounds |
| 12/29/2005 | US20050287216 Medical imaging agents for injectable compositions |
| 12/29/2005 | US20050287125 Cell delivery fluid for prevention of cell settling in delivery system |
| 12/29/2005 | US20050287074 Matrix metalloproteinase inhibitors |
| 12/29/2005 | US20050287073 Carboranylporphyrins and uses thereof |
| 12/29/2005 | US20050287072 Administering a conjugate of a biocompatible entity and a light-generating moiety; and measuring photon emission through an opaque tissue of said mammalian subject from the light-generating moiety; used for tracking the progression of infection |
| 12/29/2005 | US20050287071 Formulation for a cement preparation as bone substitute |
| 12/29/2005 | US20050287070 Ligand-specific opening of a gated-porin channel in the outer membrane of living bacteria |
| 12/29/2005 | US20050287069 Method of determining performance of an antiperspirant compositions |
| 12/29/2005 | US20050287068 Efficacy of active immunotherapy by integrating diagnostic with therapeutic methods |
| 12/29/2005 | US20050287065 Systems, methods and devices for in vivo monitoring of a localized response via a radiolabeled analyte in a subject |
| 12/29/2005 | DE102005022817A1 Kontrastmittel für ein kombinierte Betriebsarten verwendendes Bildgebungssystem und zugehörige Verfahren und Systeme Contrast agents for a combined modes-use imaging system and associated methods and systems |
| 12/29/2005 | CA2570015A1 Plural activating optical change toothpastes, stimuli and elements |
| 12/29/2005 | CA2569958A1 Abuse-deterrent drug formulations |
| 12/29/2005 | CA2569461A1 Lipophilic derivatives of chelate monoamides |
| 12/29/2005 | CA2565972A1 Ex-vivo application of solid microparticulate therapeutic agents |
| 12/28/2005 | EP1609483A1 Ultrasound contrast agent dosage formulation |
| 12/28/2005 | EP1608970A2 Ccn3 compositions and methods |
| 12/28/2005 | EP1608967A2 Compositions and methods for the diagnosis and treatment of tumor |
| 12/28/2005 | EP0971747B1 Contrast agents |
| 12/28/2005 | EP0925061B1 Compositions comprising microparticles of water-insoluble substances and method for preparing same |
| 12/28/2005 | CN1233417C Peptide P227 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes |
| 12/27/2005 | US6979738 Quadruplex stabilizer |
| 12/27/2005 | US6979450 A transdermal drug delivery device, e.g. patches, comprising topical application of an antigen and physiologically effective solution; in particular, using mycobaterial antigens to detect tuberculosis; efficient; sensitivity |
| 12/27/2005 | US6979296 Methods for ultrasonic imaging and treating diseased tissues |
| 12/22/2005 | WO2005121787A2 Lat1 transporters expressed in cancer cells |
| 12/22/2005 | WO2005121380A1 Predictive biomarkers in cancer therapy |
| 12/22/2005 | WO2005120590A1 Activatable particles, preparations and uses. |
| 12/22/2005 | WO2005120589A2 Contrast agent comprising alginate and an isotope or paramagnetic ion |
| 12/22/2005 | WO2005120588A2 Peptides delivered to cell nuclei |
| 12/22/2005 | WO2005120587A1 Ultrasound contrast agent dosage formulation |
| 12/22/2005 | WO2005120586A2 Copolymers comprising positively and negatively charged aminoacids conjugated to chelants |
| 12/22/2005 | WO2005120585A1 Dual function polymer micelles |
| 12/22/2005 | WO2005120584A2 Radiolabeled arylsulfonyl compounds and uses thereof |
| 12/22/2005 | US20050283846 Method for evaluating therapeutic agent for dermatitis and/or alopecia, therapeutic agent for dermatitis and/or alopecia, and transgenic mouse |
| 12/22/2005 | US20050283841 Inhibition of protein kinase C-related kinase (PRK) as a treatment for cardiac hypertrophy and heart failure |
| 12/22/2005 | US20050283098 Method for ultrasound triggered drug delivery using hollow microbubbles with controlled fragility |
| 12/22/2005 | US20050282889 Intracorporeal medicaments for photodynamic treatment of disease |
| 12/22/2005 | US20050282822 Therapeutic agents |
| 12/22/2005 | US20050282271 Cell; extracellular, plasma membrane associated cyto-compatible glycoconjugate, a monosaccharide; cancer diagnosis |
| 12/22/2005 | US20050281827 Trypanosome derived apoptotic factors (TAF) |
| 12/22/2005 | US20050281812 Antibodies to insulin-like growth factor I receptor |
| 12/22/2005 | US20050281748 Abuse-deterrent drug formulations |
| 12/22/2005 | US20050281747 Mixed gas microbubble compositions |
| 12/22/2005 | US20050281746 Anticoagulant contrast media |
| 12/22/2005 | US20050281745 Stable isotope based dynamic metabolic profiling of living organisms for characterization of metabolic diseases, drug testing and drug development |
| 12/22/2005 | US20050281744 Method for assessing the effect of a drug on long term memory formation |
| 12/22/2005 | US20050281743 Cancer associated protein phosphatases and their uses |
| 12/22/2005 | US20050281742 Method of determining an individual's level of tolerance to application of a product to skin of the individual, and a kit for implementing such a method |
| 12/22/2005 | US20050281741 Using cyanine dyes; in situ target tumor cells |
| 12/22/2005 | US20050281739 Imaging damaged lung tissue using compositions |
| 12/22/2005 | US20050281738 Method and means for detecting inflammatory processes |
| 12/22/2005 | DE102004045186A1 Hydratisierte lamellare Phasen oder Liposomen, enthaltend ein Fettmonoamin oder ein kationisches Polymer, das die intrazelluläre Penetration begünstigt, und kosmetische oder pharmazeutische Zusammensetzungen, diese enthaltend, sowie Screeningverfahren nach einer solchen Substanz Hydrated lamellar phases or liposomes, containing a fatty mono-amine or a cationic polymer that promotes intracellular penetration, and cosmetic or pharmaceutical compositions comprising them, as well as screening methods for such substance |
| 12/22/2005 | DE102004026494A1 Detecting specific nucleic acid comprises hybridizing peptide nucleic acid oligomer and DNA oligo where both sequences are complementary to the target and measuring fluorescent change upon mixing with target sequence which displaces oligo |
| 12/22/2005 | DE102004026103A1 Trimere makrocyclisch substituierte Aminoisophthalsäure-Halogen-Benzolderivate Trimeric macrocyclic substituted aminoisophthalic-halo-benzene derivatives |
| 12/22/2005 | DE10118792B4 Anordnung zur Aufnahme von Projektionsmammogrammen und Verwendung der Anordnung für die Projektionsmammographie Arrangement for receiving Projektionsmammogrammen and use of the arrangement for projection mammography |
| 12/22/2005 | CA2564197A1 Activatable particles, preparations and uses |
| 12/21/2005 | EP1607105A2 Tolerance determination upon application of a product on the skin |
| 12/21/2005 | EP1605996A2 Medical devices with enhanced ultrasonic visibility |
| 12/21/2005 | EP1605979A1 Conjugates for medical imaging comprising carrier, targeting moiety and a contrast agent |
| 12/21/2005 | EP1605953A2 Heterobifunctional polymeric bioconjugates |
| 12/21/2005 | EP1603451A3 Amyloid plaque as a target for therapeutics that function by blocking or disrupting chitin synthesis or activity |
| 12/21/2005 | EP1419237A4 Animal model for fatty acid amide-related neurobehaviors |
| 12/21/2005 | EP1337650A4 Transgenic animals for analysing cyp3a4 cytochrome p450 gene regulation |
| 12/21/2005 | CN1709517A Magnetic resonance tumour target contrast media and preparing method thereof |
| 12/20/2005 | US6977068 administering a colloid of a detectable marker encased in carbon; detecting the presence of the diagnostic particles binding to fibrin; |
| 12/15/2005 | WO2005119251A2 Novel means and methods for the treatment of hearing loss and phantom hearing |
| 12/15/2005 | WO2005117998A2 Smvt transporters expressed in cancer cells |
| 12/15/2005 | WO2005117997A1 Ligands having metal binding ability and targeting properties |
| 12/15/2005 | WO2005117996A2 Immune response assessment method |
| 12/15/2005 | WO2005117995A1 Application of hyaluronic acid to sentinel lymph node identification |
| 12/15/2005 | WO2005117988A1 Antibody colour pigment conjugates for changing eye color appearance |
| 12/15/2005 | WO2005117935A1 Multiple agent therapy for sexual dysfunction |